Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial

BACKGROUND: Cancer of unknown primary (CUP) is an aggressive rare malignancy with limited treatment options. Data regarding clinical activity of immune checkpoint inhibitors in CUP is lacking. Therefore, we evaluated the efficacy of pembrolizumab, a programmed cell death-1 inhibitor, in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Raghav, Kanwal P, Stephen, Bettzy, Karp, Daniel D, Piha-Paul, Sarina A, Hong, David S, Jain, Dipti, Chudy Onwugaje, Dilichukwu O, Abonofal, Abdulrahman, Willett, Anneleis F, Overman, Michael, Smaglo, Brandon, Huey, Ryan W, Meric-Bernstam, Funda, Varadhachary, Gauri R, Naing, Aung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125753/
https://www.ncbi.nlm.nih.gov/pubmed/35618285
http://dx.doi.org/10.1136/jitc-2022-004822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125753/
https://www.ncbi.nlm.nih.gov/pubmed/35618285
http://dx.doi.org/10.1136/jitc-2022-004822

Ejemplares similares